About

Shield Therapeutics is a high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.

Explore section

Lead Products

Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.

Explore section

Investors

Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.

Explore section

Careers

As a unified team we are constantly driven by and committed to our goals, seeking to deliver them with transparency and respect. Being consistent to this vision, while enjoying the journey, has brought us to where we are today.

Explore section

All jobs

Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

1 Oct 2018

Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more details please see the press release below.

STX_NDA submission

Back to news

Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

Sign up for news